Vaccination is termed as a cost-effective and efficient means of preventing various infectious disorders. The use of common vaccines has curbed the widespread transmission of diseases such as polio and measles in developing as well as developed regions. Oral vaccines exhibit the potential to take immunization to a new level of excellence. Although most vaccines are delivered via the parenteral route, oral vaccines are considered to be a feasible & cost-effective alternative employed for the prevention of non-mucosal transmitted infections. Orally administered vaccines are processed by the digestive tract's immune system, referred to as the gut-associated lymphoid tissue (GALT). To increase immunity against vital disorders such as influenza and tuberculosis (TB), new oral vaccines are being produced in developed countries.
Elimination of needles in the vaccination process and their safe & cost effective nature are driving the oral vaccines market remarkably. The rising prevalence of infectious diseases in developing countries, resistance to existing vaccines, and bioterrorism are some of the factors expected to push the market from 2017 to 2025. However, oral vaccination is considered to be less effective compared to vaccines administered via parenteral routes, as in the former method, antigens undergo digestion in the gastrointestinal tract prior to the induction of immune response. This could restrain the market over the forecast period.
The global oral vaccines market can be segmented on the basis of vaccine type into the live (attenuated), inactive, recombinant, and other varieties. The inactive segment accounted for a major chunk of the market revenue in 2016 due to its safety and cost-effectiveness. It is likely to remain dominant over the forecast period owing to the expanding patient pool in national immunization programs.
Based on application, the global oral vaccines market is divided into the following categories: polio, rabies, tuberculosis, influenza, respiratory infections, HIV, cholera, rotavirus, and others. The influenza and HIV segments constituted a major portion of the revenue in 2016, due to their rising prevalence in developing countries. Oral vaccines for tuberculosis, HIV, and influenza are projected to dominate the market over the forecast period due to their increasing development by key players and comparatively lower cost.
By end-user, the global oral vaccines market is split into the following groups: hospitals, government vaccination programs, clinics, and research institutes. Clinics and government vaccination programs held major market shares in 2016, which is attributed to the government participation in the prevention and treatment of infectious disorders in developing countries and rising investments by key players in R&D of invention of better and efficient medication. Government vaccination programs are estimated to remain dominant in the market by 2025 due to the resistance of the population for existing vaccines and favorable government reimbursement schemes.
Geographically, the global oral vaccines market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America captured a prominent market share in 2016 owing to the high purchasing power of the region’s population to afford costly vaccines and the periodical mass immunization programs held by the government. The need to avoid the risk of contamination by needles & syringes and recent USFDA approvals for oral vaccines for infectious diseases such as tuberculosis & cholera are estimated to propel the oral vaccines market in North America during the forecast period. However, Asia Pacific is expected to witness a significant CAGR on account of the rising incidence of HIV and influenza in developing countries.
Major players operating in the global oral vaccines market include GlaxoSmithKline Plc., Merck & Co. Inc., Aventis (Sanofi S.A.), Swiss Serum and Vaccine Institute Berne, QUÍMICA SUIZA S.A., PaxVax Corporation, VALNEVA Canada Inc., Janssen Pharmaceuticals, Serum Institute of India Pvt. Ltd., and Shanghai BravoBio Co., Ltd. Presently, a limited number of oral vaccines has been approved by regulatory authorities for human use and many more are in their later stages of clinical trials.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.